Table 3 Anticancer applications in clinical trials
From: CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology
Applications | Target site | Study phase | Editing strategy | Clinical trials identification |
|---|---|---|---|---|
Advanced esophageal cancer | PD-1 | Phase II | PD-1 knockout | NCT03081715 |
Castration resistant prostate cancer | PD-1 | Phase I | PD-1 knockout | NCT02867345 |
Muscle-invasive bladder cancer | PD-1 | Phase I | PD-1 knockout | NCT02863913 |
Metastatic non-small cell lung cancer | PD-1 | Phase I | PD-1 knockout | NCT02793856 |
EBV associated malignancies | PD-1 | Phase I Phase II | PD-1 knockout | NCT03044743 |
Metastatic renal cell carcinoma | PD-1 | Phase I | PD-1 knockout | NCT02867332 |
Relapsed or refractory leukemia and lymphoma | CD19 and CD20 or CD22 | Phase I Phase II | Edit CD19 and CD20 or CD22 | NCT03398967 |
Human papillomavirus-related malignant neoplasm | HPV16-E6/E7 HPV18 E6/E7 | Phase I | HPV16-E6/E7 or HPV18 E6/E7 knockout | NCT03057912 |
CD19 + leukemia and lymphoma | TCR B2M | Phase I Phase II | TCR and B2M knockout | NCT03166878 |
Tumor of the central nervous system | NF1 | — | Fix NF1 mutation allele | NCT03332030 |
Multiple myeloma Melanoma Synovial sarcoma Myxoid/round cell liposarcoma | TCR PD-1 | Phase I | TCR and PD-1 knockout | NCT03399448 |
